Patient and treatment characteristics (N = 512)
Parameter . | N (%) . |
---|---|
Median age, years | 58 |
Range | 20-90 |
Female sex | 254 (49.6) |
ECOG PS 0-1 | 509 (99.4) |
Stage I disease | 410 (80.1) |
Extranodal disease | 113 (22.1) |
B symptoms | 3 (0.6) |
Stage II disease | 102 (19.9) |
Extranodal disease | 14 (2.7) |
B symptoms | 2 (0.4) |
Grade | |
1-2 | 460 (89.8) |
3A or 3 NOS | 52 (10.2) |
Median RT dose, Gy | 30 |
Range | 24-52 |
24-30 | 345 (67.4) |
>30-36 | 140 (27.3) |
>36 | 27 (5.3) |
Median pretreatment size, cm | 2.8 |
Range | 0.2-10 |
Unknown | 45 (8.8) |
Median follow-up, mo | 52.3 |
Range | 3.2-174.6 |
BCL2 expression | |
Positive | 281 (54.9) |
Negative | 133 (26.0) |
Unknown | 98 (19.1) |
Parameter . | N (%) . |
---|---|
Median age, years | 58 |
Range | 20-90 |
Female sex | 254 (49.6) |
ECOG PS 0-1 | 509 (99.4) |
Stage I disease | 410 (80.1) |
Extranodal disease | 113 (22.1) |
B symptoms | 3 (0.6) |
Stage II disease | 102 (19.9) |
Extranodal disease | 14 (2.7) |
B symptoms | 2 (0.4) |
Grade | |
1-2 | 460 (89.8) |
3A or 3 NOS | 52 (10.2) |
Median RT dose, Gy | 30 |
Range | 24-52 |
24-30 | 345 (67.4) |
>30-36 | 140 (27.3) |
>36 | 27 (5.3) |
Median pretreatment size, cm | 2.8 |
Range | 0.2-10 |
Unknown | 45 (8.8) |
Median follow-up, mo | 52.3 |
Range | 3.2-174.6 |
BCL2 expression | |
Positive | 281 (54.9) |
Negative | 133 (26.0) |
Unknown | 98 (19.1) |
Continuous variables are shown with ranges, and categorical variables with percentages in parentheses.
ECOG PS, Eastern Cooperative Oncology Group performance score; NOS, not otherwise specified.